INTRODUCTION: Chronic kidney disease may complicate diabetes, often manifesting with reduced glomerular filtration rate (GFR), albuminuria, or both. Although greater albuminuria and lower estimated GFR both predict adverse prognosis, whether a synergistic prognostic interaction occurs in patients with diabetes has not been defined in a large national cohort study. METHODS: We used 2000-2011 data from the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) for 42,761 participants with diabetes. Kaplan-Meier survival analysis and multivariable Cox regression were used to ascertain the association of estimated GFR, albumin-creatinine ratio (ACR), and their interaction on all-cause mortality and progression to end-stage renal disease (ESRD) at a median 4 years of follow-up. RESULTS: Of 42,761 participants with diabetes, 8,618 (20.2%) had estimated GFR <60 mL/min/1.73 m(2), 7,715 (18.0%) had ACR >30 mg/g, and 2,641 (6.2%) had both. The unadjusted incidence (per 1,000 person-years) of all-cause mortality increased from 3.1 (95% CI, 2.4-3.8) in participants with estimated GFR ≥ 105 mL/min/1.73 m(2) and no albuminuria to 73.7 (95% CI, 54.9-92.5) in participants with estimated GFR <30 mL/min/1.73 m(2) and macroalbuminuria (P < 0.001). Progression to ESRD likewise increased from 0.2 (95% CI, 0-0.4) to 220.4 (95% CI, 177.2-263.6) per 1,000 person-years (P < 0.001). After adjustment for confounders, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction (P for interaction < 0.001); estimated GFR <30 mL/min/1.73 m(2) and macroalbuminuria together were associated with a 5-fold higher risk of mortality and a more than 1,000-fold higher risk of progression to ESRD (compared with patients with estimated GFR >60 mL/min/1.73 m(2) and ACR <30 mg/g; P < 0.001 for both outcomes). CONCLUSIONS: In this large cohort of diabetic KEEP participants with more than 170,000 person-years of follow-up, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction.
INTRODUCTION:Chronic kidney disease may complicate diabetes, often manifesting with reduced glomerular filtration rate (GFR), albuminuria, or both. Although greater albuminuria and lower estimated GFR both predict adverse prognosis, whether a synergistic prognostic interaction occurs in patients with diabetes has not been defined in a large national cohort study. METHODS: We used 2000-2011 data from the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) for 42,761 participants with diabetes. Kaplan-Meier survival analysis and multivariable Cox regression were used to ascertain the association of estimated GFR, albumin-creatinine ratio (ACR), and their interaction on all-cause mortality and progression to end-stage renal disease (ESRD) at a median 4 years of follow-up. RESULTS: Of 42,761 participants with diabetes, 8,618 (20.2%) had estimated GFR <60 mL/min/1.73 m(2), 7,715 (18.0%) had ACR >30 mg/g, and 2,641 (6.2%) had both. The unadjusted incidence (per 1,000 person-years) of all-cause mortality increased from 3.1 (95% CI, 2.4-3.8) in participants with estimated GFR ≥ 105 mL/min/1.73 m(2) and no albuminuria to 73.7 (95% CI, 54.9-92.5) in participants with estimated GFR <30 mL/min/1.73 m(2) and macroalbuminuria (P < 0.001). Progression to ESRD likewise increased from 0.2 (95% CI, 0-0.4) to 220.4 (95% CI, 177.2-263.6) per 1,000 person-years (P < 0.001). After adjustment for confounders, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction (P for interaction < 0.001); estimated GFR <30 mL/min/1.73 m(2) and macroalbuminuria together were associated with a 5-fold higher risk of mortality and a more than 1,000-fold higher risk of progression to ESRD (compared with patients with estimated GFR >60 mL/min/1.73 m(2) and ACR <30 mg/g; P < 0.001 for both outcomes). CONCLUSIONS: In this large cohort of diabetic KEEP participants with more than 170,000 person-years of follow-up, both estimated GFR and albuminuria were associated independently with mortality and progression to ESRD, with a strong synergistic interaction.
Authors: Richard J MacIsaac; Sianna Panagiotopoulos; Karen J McNeil; Trudy J Smith; Con Tsalamandris; Huming Hao; P Geoffrey Matthews; Merlin C Thomas; David A Power; George Jerums Journal: Diabetes Care Date: 2006-07 Impact factor: 19.112
Authors: Giuseppe Pugliese; Anna Solini; Enzo Bonora; Emanuela Orsi; Gianpaolo Zerbini; Francesco Giorgino; Franco Cavalot; Antonio E Pontiroli; Marco G Baroni; Susanna Morano; Antonio Nicolucci; Giuseppe Penno Journal: Atherosclerosis Date: 2011-05-06 Impact factor: 5.162
Authors: D J Newman; M B Mattock; A B S Dawnay; S Kerry; A McGuire; M Yaqoob; G A Hitman; C Hawke Journal: Health Technol Assess Date: 2005-08 Impact factor: 4.014
Authors: P A McCullough; A Whaley-Connell; W W Brown; A J Collins; S-C Chen; S Li; K C Norris; C Jurkovitz; S McFarlane; C Obialo; J Sowers; L Stevens; J A Vassalotti; G L Bakris Journal: Intern Med J Date: 2010-12 Impact factor: 2.048
Authors: Adam Whaley-Connell; Andrew S Bomback; Samy I McFarlane; Suying Li; Tricia Roberts; Shu-Cheng Chen; Allan J Collins; Keith Norris; George L Bakris; James R Sowers; Peter A McCullough Journal: Cardiorenal Med Date: 2011-01-17 Impact factor: 2.041
Authors: Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey Journal: JAMA Date: 2012-05-09 Impact factor: 56.272
Authors: Dominik G Haider; Salome Masghati; Georg Goliasch; Valentin Fuhrmann; Afschin Soleiman; Michael Wolzt; Andreas Baierl; Wilfred Druml; Walter H Hörl Journal: J Nephrol Date: 2014-03-08 Impact factor: 3.902
Authors: Toshiaki Ohkuma; Min Jun; John Chalmers; Mark E Cooper; Pavel Hamet; Stephen Harrap; Sophia Zoungas; Vlado Perkovic; Mark Woodward Journal: Clin J Am Soc Nephrol Date: 2019-06-03 Impact factor: 8.237
Authors: Daniel E Weiner; Meyeon Park; Hocine Tighiouart; Alin A Joseph; Myra A Carpenter; Nitender Goyal; Andrew A House; Chi-Yuan Hsu; Joachim H Ix; Paul F Jacques; Clifton E Kew; S Joseph Kim; John W Kusek; Todd E Pesavento; Marc A Pfeffer; Stephen R Smith; Matthew R Weir; Andrew S Levey; Andrew G Bostom Journal: Am J Kidney Dis Date: 2018-07-20 Impact factor: 8.860
Authors: Dominik Steubl; Markus P Schneider; Heike Meiselbach; Jennifer Nadal; Matthias C Schmid; Turgay Saritas; Vera Krane; Claudia Sommerer; Seema Baid-Agrawal; Jakob Voelkl; Fruzsina Kotsis; Anna Köttgen; Kai-Uwe Eckardt; Jürgen E Scherberich Journal: Clin J Am Soc Nephrol Date: 2020-04-14 Impact factor: 8.237
Authors: Adam T Whaley-Connell; Manjula Kurella Tamura; Claudine T Jurkovitz; Mikhail Kosiborod; Peter A McCullough Journal: Am J Kidney Dis Date: 2013-04 Impact factor: 8.860
Authors: Shristi Rawal; Sjurdur F Olsen; Louise G Grunnet; Ronald C Ma; Stefanie N Hinkle; Charlotta Granström; Jing Wu; Edwina Yeung; James L Mills; Yeyi Zhu; Wei Bao; Sylvia H Ley; Frank B Hu; Peter Damm; Allan Vaag; Michael Y Tsai; Cuilin Zhang Journal: Diabetes Care Date: 2018-05-04 Impact factor: 17.152